Dova Pharmaceuticals (DOVA) Stock Price, News & Analysis

Company Overview

Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.

Key Stats

• Today's Range: $28.04 to $28.04
• 50-Day Range: $28.04 to $28.04
• 52-Week Range: $5.62 to $28.54
• Volume: 35,036 shs
• Average Volume: 499,313 shs
• Market Capitalization: $807.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DOVA Stock Analysis - Frequently Asked Questions

How were Dova Pharmaceuticals' earnings last quarter?

Dova Pharmaceuticals Inc (NASDAQ:DOVA) issued its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by $0.03. The company earned $3.52 million during the quarter, compared to analyst estimates of $5.63 million. Dova Pharmaceuticals had a negative trailing twelve-month return on equity of 101.60% and a negative net margin of 544.09%.

When did Dova Pharmaceuticals IPO?

Dova Pharmaceuticals (DOVA) raised $66 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 4,100,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners served as the underwriters for the IPO.

What other stocks do shareholders of Dova Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Dova Pharmaceuticals investors own include Global Blood Therapeutics (GBT), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Fate Therapeutics (FATE), Fibrocell Science (FCSC), Tesaro (TSRO) and Viking Therapeutics (VKTX).

Company Calendar

• Last Earnings: 8/06/2019
• Today: 8/03/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:DOVA
• CIK: 1685071
• Web: www.dova.com
• Phone: 919-748-5975
• Fax: N/A
• Employees: 115
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$72.28 million
• Net Margins: -544.09%
• Pretax Margin: N/A
• Return on Equity: -101.60%
• Return on Assets: -67.21%

Debt

• Debt-to-Equity Ratio: 0.41
• Current Ratio: 5.64
• Quick Ratio: 5.37

Sales & Book Value

• Annual Sales: $10.35 million
• Price / Sales: 78.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.71 per share
• Price / Book: 10.35

Miscellaneous

• Outstanding Shares: 28,800,000
• Free Float: N/A
• Market Cap: $807.55 million
• Optionable: Optionable
• Beta: 2.74